In the experiments, the researchers used gene therapy to ramp up FGF21 production in the livers of mice that develop obesity and a NASH-like condition when fed a high-fat diet for 23 weeks. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.